Novel Molecular Classification of Breast Cancer with PET Imaging DOI Creative Commons
Ngô Minh Toàn

Medicina, Journal Year: 2024, Volume and Issue: 60(12), P. 2099 - 2099

Published: Dec. 21, 2024

Breast cancer is a heterogeneous disease characterized by wide range of biomarker expressions, resulting in varied progression, behavior, and prognosis. While traditional biopsy-based molecular classification the gold standard, it invasive limited capturing tumor heterogeneity, especially deep or metastatic lesions. Molecular imaging, particularly positron emission tomography (PET) offering non-invasive alternative, potentially plays crucial role management breast providing detailed information about location, progression. This narrative review, which focuses on both clinical patients preclinical studies, explores latest advancements PET imaging for cancer, emphasizing development new tracers targeting hormone receptors such as estrogen alpha receptor, progesterone androgen beta well ErbB family receptors, VEGF/VEGFR, PARP1, PD-L1, markers indirectly assessing Ki-67. These innovative radiopharmaceuticals have potential to guide personalized treatment approaches based unique profiles individual patients. Additionally, they may improve assessment efficacy, ultimately leading better outcomes those diagnosed with cancer.

Language: Английский

Post-Progression treatment options after CDK4/6 inhibitors in hormone Receptor-Positive HER2-Negative metastatic breast cancer DOI
Taha Koray Şahin, Alessandro Rizzo, Deniz Can Güven

et al.

Cancer Treatment Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102924 - 102924

Published: March 1, 2025

Language: Английский

Citations

2
Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets DOI Open Access
Amalia A. Sofianidi,

Ecaterina E. Dumbrava,

Konstantinos N. Syrigos

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(6), P. 1139 - 1139

Published: March 13, 2024

Worldwide, breast cancer is the most frequently diagnosed malignancy in women, with triple-negative (TNBC) being aggressive molecular subtype. Due to dearth of effective therapeutic options for TNBC, novel agents targeting key mechanisms and pathways cells are continuously explored; these include ATR inhibitors, which target kinase involved DNA damage response (DDR) pathway, CHK1/2 Checkpoint Kinase 1/2 (CHK1/2) cell cycle arrest repair. inhibitors show potential as prospective treatments TNBC by focusing on DDR interfering regulation cells. Preliminary preclinical clinical findings suggest that when combined chemotherapy, demonstrate significant anti-proliferative efficacy against TNBC. In this article, we introduce promising approaches management Preclinical studies performed evaluating treatment associated challenges encountered context date reviewed.

Language: Английский

Citations

9
Advanced and Metastatic Triple Negative Breast Cancer—Potential New Treatment DOI Open Access
Monika Pajewska, Olga Partyka, Aleksandra Czerw

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(7), P. 1183 - 1183

Published: March 31, 2025

Globally, breast cancer is both the most common and cause of death related to among women. It estimated that over 2 million women were diagnosed with in 2022 worldwide, while almost 400,000 EU. Breast has different histopathological subtypes require therapeutic approaches. Triple-negative (TNBC) a type considered more aggressive; it occurs about 10 20% all cases. Approximately 40% initially TNBC will develop metastases. The objective this study present current clinical trials focused on new treatment advanced metastatic TNBC. was conducted by searching clinicaltrials.gov database. Due scope paper, primary endpoints included studies response rate, treatment-emergent adverse events or serious events, progression-free survival, probability pathologic complete response. Some selected phase I II RCTs; therefore, we should carefully examine their future results implications for guidelines.

Language: Английский

Citations

1
Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy DOI Creative Commons
Yunfeng Wu, Yu-xi Liu, Han Wu

et al.

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 1425 - 1442

Published: Feb. 1, 2025

Abstract: Breast cancer is one of the most common types in women worldwide and a leading cause deaths among women. As result, various treatments have been developed to combat this disease. treatment varies based on its stage type pathology. Among therapeutic options, ultrasound has employed assist breast cancer, including radiation therapy, chemotherapy, targeted immunotherapy, hormonal and, more recently, radiofrequency ablation for early-stage inoperable patients. One notable advancement ultrasound-targeted microbubble destruction (UTMD), which gradually becoming highly effective non-invasive anti-tumor modality. This technique can enhance chemical, genetic, immune, anti-vascular therapies through physical biological effects. Specifically, UTMD improves drug transfer efficiency destroys tumor neovascularization while reducing toxic side effects body during treatment. Given these developments, application ultrasound-assisted therapy gained significant attention from research scholars. In review, we will discuss development modalities importantly, highlight microbubble-targeted disruption techniques Keywords: destruction, microbubble, TME,

Language: Английский

Citations

0
Trastuzumab Deruxtecan (T-Dxd) in Metastatic Breast Cancer with Different Her2 Expression Levels: A Real-World Effectiveness and Safety Study DOI
Lan Xu, Qinglin Zhang, Ziwen Zhang

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
The impact of the new Histological classification of breast cancer with the introduction of Her 2 low status. DOI

Michèle Doucet,

Marion deberti,

Flavie Arbion

et al.

Journal of Gynecology Obstetrics and Human Reproduction, Journal Year: 2025, Volume and Issue: unknown, P. 102928 - 102928

Published: Feb. 1, 2025

Language: Английский

Citations

0
A multifunctional Pt/DMSN nanozyme-based colorimetric-fluorescence sensing platform for breast cancer detection DOI

Xinrui Xue,

Zheng Fang,

Yujia Luo

et al.

Microchimica Acta, Journal Year: 2025, Volume and Issue: 192(4)

Published: March 13, 2025

Language: Английский

Citations

0
Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis DOI Creative Commons
Francisco Cézar Aquino de Moraes, Caio Henrique Duarte de Castro Ribeiro, Felipe Dircêu Dantas Leite Pessôa

et al.

Breast Cancer Research, Journal Year: 2025, Volume and Issue: 27(1)

Published: March 15, 2025

Currently, the primary methods for detecting HER2 expression levels are immunohistochemistry (IHC) and in situ hybridization (ISH), with traditional standard being a HER2-positive score of 3 + accompanied by ERBB2 gene amplification detected through ISH. However, new entity has recently emerged: HER2-low, defined as IHC 1 or 2 negative HER2-low breast cancer, representing 45–60% all HER2-negative tumors, distinct biological characteristics uncertain responses to conventional HER2-targeted therapies. Recent studies suggest varied clinical outcomes, highlighting need further investigation into impact status on treatment efficacy prognosis. This meta-analysis evaluates difference complete pathological response (pCR), disease-free survival (DFS), overall (OS) between HER2-zero phenotypes. We systematically searched main databases PubMed, Scopus, Web Science articles evaluating women neoadjuvant therapy expressing HER2-zero. computed odds ratios (ORs) hazard (HRs) using DerSimonian Laird random-effect models endpoints, 95% confidence intervals (CIs). assessed heterogeneity I2 statistics. R, version 4.2.3, was used statistical analyses. 38 totaling 70,104 patients were included. The group accounted 61.3% while HR represented 52.4% whole research. In 67,839 women, pCR analyzed, which cohort analysis favored (OR 0.84; CI 0.78–0.90; p = 0.000005; 15%). Subgroup analyses triple-negative cancer (TNBC) also expression, an OR 0.91 (95% 0.83–1.0; < 0.041; 12%) 0.75 0.70–0.81; 0.000001; 0%), respectively. multivariate across patients, both DFS OS outcomes significantly favorable group, 0.8317 0.7036–0.9832; 0.031) 0.806 0.663–0.979; 0.03) OS. Based our findings, is associated higher (pCR) rate compared early-stage other outcomes. These results that should be considered prognostic factor taken account planning future

Language: Английский

Citations

0
Redefining therapeutic landscapes: clinicopathological insights into low and ultra-low HER2 expression in male breast cancer DOI Creative Commons

Jiuyan Shang,

Jiaxian Miao,

Shuyao Niu

et al.

Diagnostic Pathology, Journal Year: 2025, Volume and Issue: 20(1)

Published: April 15, 2025

Abstract Objective With the emergence of new antibody coupled drugs, treatment decisions patients with low and ultra-low HER2 expression have been reshaped. However, epidemiological characteristics relatively rare male breast cancer are still unclear. This study discusses clinicopathological immunophenotypic invasive expression. Methods The features 106 cases were retrospectively analyzed. was evaluated according to ASCO/CAP guidelines. cutoff value positive cell staining > 10%. negative divided into (IHC = 1+/2 + ISH without amplification) HER2-0 (IHC-0, null < 10% weak membrane). prognosis collected. Results from 2015 2024 included in this study, more than 85% histological types ductal carcinoma. Immunophenotype: There 23 HER2-zero (including 13 ultra-low), 72 low, 11 positive, rate 10.38%, incidence 67.93%; significantly higher that female cancer, difference statistically significant ( P 0.05). In terms prognosis, there no statistical between survival different status cohort. Conclusion Male is rare, it common elderly over 60 years old. ER PR high, high. high can provide a anti-HER2 decision.

Language: Английский

Citations

0
Development and clinical evaluation of [68Ga]Ga-NODAGA-ADAPT6 as a novel HER2-targeted PET radiotracer for breast cancer imaging and treatment monitoring DOI
Weijing Tao, Jinglin Zhang,

Xin Meng

et al.

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2025, Volume and Issue: unknown

Published: April 21, 2025

Language: Английский

Citations

0